CDKN2A and ductal breast carcinoma in situ: Importantly, subsequent direct analysis of RB loss in DCIS by optimized immunohistochemistry revealed that RB loss is one of the strongest markers of DCIS recurrence and progression that has been identified and does occur in tumors that express high levels of p16ink4a [51] (Figure 3).